AKTS Earnings Date: Nov 12, 2026 (Estimated) — Aktis Oncology, Inc.
NASDAQ
Updated
When is AKTS's next earnings date?
Aktis Oncology, Inc. (AKTS) is expected to report Q3 2026 earnings on Thursday, November 12, 2026 at 9:13 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.47 on revenue of $4.0M.
How did AKTS do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Aktis Oncology, Inc. posted EPS of -$0.44 versus the -$0.43 estimate, a miss of 2.3%. Revenue was $3.4M against a $2.6M estimate. The stock's 1-day post-earnings move was +4.8%.
How much does AKTS stock move after earnings?
AKTS beat EPS estimates in 1 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 14.4% (up or down) in the day after earnings.
About Aktis Oncology, Inc.
Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.43 | -0.44 | -2.33% | $3.4M | ❌ Miss | +4.79% | +0.88% | -2.61% |
| 2026-05-11 | Q1 2026 | -0.33 | -0.38 | -15.15% | $3.2M | ❌ Miss | +7.99% | +1.86% | +1.70% |
| 2024-11-14 | Q1 2025 | -0.11 | -0.04 | +63.64% | $9.0M | ✅ Beat | +13.59% | +84.93% | +44.80% |
| 2024-10-08 | Q4 2024 | -0.10 | -1.14 | -1040.00% | $5.9M | ❌ Miss | +11.88% | -0.40% | -20.96% |
| 2024-05-13 | Q3 2024 | -0.12 | -0.14 | -16.67% | $7.5M | ❌ Miss | -26.30% | -37.30% | -72.77% |
| 2024-02-13 | Q2 2024 | -0.18 | -0.19 | -5.56% | $7.0M | ❌ Miss | -15.06% | +8.53% | -17.72% |
| 2023-11-13 | Q1 2024 | -0.18 | -0.27 | -50.00% | $7.0M | ❌ Miss | +5.68% | +26.46% | +2.62% |
| 2023-09-06 | Q4 2023 | -0.17 | -0.21 | -2352.94% | $8.3M | ❌ Miss | -29.70% | -40.61% | -55.10% |
Showing last 8 quarters.